Background: Opioids can produce life-threatening respiratory depression. This study tested whether subanaesthetic doses of esketamine stimulate breathing in an established human model of opioid-induced respiratory depression. Methods: In a study with a randomised, double blind, placebo controlled, crossover design, 12 healthy, young volunteers of either sex received a dose escalating infusion of esketamine (cumulative dose 40 mg infused in 1 h) on top of remifentanil-induced respiratory depression. A population pharmacokinetic-pharmacodynamic analysis was performed with sites of drug action at baseline ventilation, ventilatory CO 2 -chemosensitivity, or both. Results: Remifentanil reduced isohypercapnic ventilation (end-tidal PCO 2 6.5 kPa) by approximately 40% (from 20 to 12 litre min À1 ) in esketamine and placebo arms of the study, through an effect on baseline ventilation and ventilatory CO 2
The observation that opioids produce life-threatening respiratory depression is not new. The first reported death from i.v. morphine dates from the 1850s when Englishman Alexander Wood injected his wife with morphine just after the introduction of the hollow needle. 1 Public awareness of the potentially life-threatening adverse effects of opioids is new, however, and is related to the recent escalation of prescribed opioid consumption and prescribed opioid deaths in the USA and other western countries. 2e4 The combination of opioid misuse and cardiorespiratory depression in particular is potentially lethal. While it is well established that the increase in deaths occurs in patients that consume opioids in the community (i.e. opioids prescribed for treatment of chronic pain), opioid-induced respiratory depression (OIRD) is an equally relevant problem for patients treated with potent opioids in the acute or hospital setting. In recent years, various pharmacological interventions have been proposed to offset OIRD, most of which are respiratory stimulants that do not interact with the opioid receptor system, so that opioid analgesia is not compromised. 8 While For Permissions, please email: permissions@elsevier.com some of these drugs are registered respiratory stimulants (e.g. doxapram), others are experimental drugs that require further research (ampakines, 5HT-agonsists, methylxanthines, drugs acting at background potassium channels of type 1 carotid body cells). 8e11 In the current study, we assess whether the commonly used anaesthetic esketamine is able to reverse, at subanaesthetic dose, (part of) the respiratory depression induced by a potent opioid. Recent animal and human data suggest that ketamine is a respiratory stimulant and consequently may possibly offset OIRD. 12e15 Ketamine is different from other respiratory stimulants in that it has inherent analgesic properties. Consequently, if ketamine is able to reverse OIRD, it may also reduce opioid consumption. 16 We performed two studies. The first was a double blind, randomised, placebo-controlled, crossover trial designed as a proof-of-concept study to investigate the effect of doseescalating infusions of esketamine (four steps with a cumulative dose of 40 mg per 70 kg given in 1 h) on opioid-induced respiratory depression under isohypercapnic conditions. We measured esketamine plasma concentrations and minute ventilation and performed a population pharmacokinetic (PK)epharmacodynamic (PD) analysis. We hypothesise that (low-dose) esketamine will effectively reduce remifentanilinduced respiratory depression. To further understand esketamine's effect on ventilation, we next examined, in an observational study, whether esketamine is a respiratory stimulant when respiration is not depressed by an opioid.
Methods

Ethics and subjects
This single-centre, double blind, placebo-controlled, crossover study protocol was performed from November 2016 to July 2017 at the Anesthesia and Pain Research Unit of the Department of Anesthesiology at the Leiden University Medical Center. The local Institution Review Board (Commissie Medische Ethiek, Leiden, The Netherlands) and the Central Committee on Research involving Human Subjects (CCMO, The Hague, The Netherlands) approved the study protocol. Written informed consent was obtained from all participants before enrolment. All study procedures were conducted according to good clinical practice guidelines and adhered to the tenets of the Declaration of Helsinki. Participants were recruited by flyers posted on the campus of the university. The study was registered in the Dutch trial register (identifier 6248).
Healthy volunteers, aged 18e40 yr, with a body mass index <30 kg m À2 and able to read and understand the subject information form were recruited. Exclusion criteria were: a medical history of medical or psychiatric disease; any allergy to food or medication; alcohol abuse (i.e. >21 units per week); smoking; pregnancy or lactation; participation in an investigational drug trial in the 3 months before the current study; illicit drug use in the 30 days before the current study; or a positive urine dipstick on the screening or study days. The dipstick (Alere Toxicology Plc, Oxfordshire, UK) tests for cocaine, amphetamine, cannabinoids, phencyclidine, methadone, benzodiazepine, tricyclic antidepressants, and barbiturates. Subjects were asked not to eat and drink for 8 h before dosing, not to take caffeinated drinks, chocolate drinks or alcohol for 24 h before dosing and to refrain from grapefruit (juice) for 7 days before the first study visit and thereafter for the duration of the study.
Study design
Subjects visited the research unit on three separate occasions, at least 1 week apart. On visits 1 and 2, the effect of esketamine (Ketanest-S, Pfizer, The Netherlands) on opioid-induced respiratory depression was tested using a double-blind placebocontrolled, crossover design. Subjects were randomised to receive either esketamine or placebo (normal saline) on top of remifentanil (GlaxoSmithKline BV, The Netherlands) induced respiratory depression. On the third occasion, the effect of just esketamine on ventilation was studied (i.e. without remifentanil). Subjects received two i.v. access lines (one for esketamine or placebo and the other for remifentanil infusion) and a 22 G cannula in the left or right radial artery for blood sampling. During the study day, subjects were monitored by ECG, oxygen saturation via a finger probe and blood pressure through the arterial line.
Drug administration
Remifentanil was administered i.v. by target-controlled infusion on visits 1 and 2 ( Supplementary Fig. S1 ). The remifentanil target controlled infusion system makes use of Minto and colleagues' 17 pharmacokinetic data set. The target concentration was started at 0.5 ng ml À1 and step-wise increased to a specific end-point (i.e. a decrease in ventilation by 40e50% of baseline value). Titration to effect was performed with steps in target remifentanil concentration of 0.1e0.5 ng ml À1 . After ventilation had reached a steady state for at least 10 min, the esketamine/placebo infusion began. Esketamine or placebo were administered by i.v. dose-escalating infusions over 60 min: 0e15 min 4 mg (step 1), 15e30 min 8 mg (step 2), 30e45 min 12 mg (step 3) and 45e60 min 16 mg (step 4); all doses are per 70 kg. After the 1 h esketamine infusion, the remifentanil infusion continued for another 15 min (see also Fig. 1 ). In case ventilation reached baseline values during steps 1, 2, or 3, a next step increase in ketamine was not performed and the esketamine infusion was ended at the end of the 15 min infusion of that particular step.
Ventilation measurements
On all three occasions, ventilation was measured on a breathto-breath basis using the Dynamic End-Tidal Forcing , while end-tidal PO 2 was strictly maintained at a normoxic value (14.5 kPa). When ventilation reached a steady state under these isohypercapnic and iso-oxic conditions the remifentanil infusion was started followed by the esketamine or placebo infusion. After the remifentanil infusion had ended, ventilation measurements at isohypercapnic and iso-oxic conditions continued for another 15 min.
On the third visit, ventilation was measured under poikilocapnic conditions (i.e. without CO 2 clamping). The esketamine administration was similar to the infusion scheme of visit 1 or 2, however, without administration of remifentanil. Minute ventilation and end-tidal PCO 2 averages were calculated and used in the data analysis. 
Sedation and drug high assessment
At the end of drug infusion, sedation and drug high were measured on an 11-point verbal rating scale (VRS) ranging from 0 (no effect) to 10 (maximum effect).
Blood sampling
To quantify the esketamine concentrations, arterial blood samples were collected in 6-ml heparin tubes. Blood samples were obtained at baseline (before any esketamine infusion) and t¼1, 4, 10, 15, 17, 25, 30, 32, 40, 45, 47, 55, 60, 62, 65, 70, 80, 90 , and 120 min after the start of esketamine infusion ( Supplementary Fig. S1 ). Within 30 min after collection, blood samples were centrifuged at 450 g for 15 min at 4 C; 2e3 ml plasma was separated and stored at e80 C until analysis. Esketamine measurements were performed at the University of Groningen on a TSQ Quantum™ Access MAX Triple Quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) using a Vanquish autosampler (Thermo Fisher Scientific) and injections of 5 ml. The linear range of the assay was 2.5e2000 ng ml À1 ; the lower limit of quantitation was 0.5 ng ml À1 for esketamine. The data were analysed using Xcalibur software (Thermo Fisher Scientific).
Randomisation and allocation
Randomisation was performed using a computer-generated randomisation list by an individual not involved in the study after all relevant parties (institutional and national review boards, pharmacy, departmental research board) approved the study protocol. The randomisation list was used by the pharmacy to prepare the study medication. The researchers notified the pharmacy of the subject number on the day before the study. Esketamine or saline were delivered to the laboratory on the morning of the study in syringes labelled with subject and visit numbers (1 or 2) only. The research team prepared all other medication. The team remained blinded to treatment until the data acquisition was completed.
Data analysis
A population PKePD model was constructed in which the esketamine's PK was linked to the remifentanil potency parameter (i.e. C 50 or the concentration remifentanil that reduced ventilation by 50%). The population analyses were performed in NONMEM version 7.4.1 (software for nonlinear mixed effects modelling; Icon plc, Gaithersburg, MD, USA). Model selection was based on the minimum objective function value (c 2 test), standard error of estimates (SEE) and goodness of fit plots. For both PK and PD analysis, the model parameters were assumed to be log-normally distributed across the population. Residual error was assumed to have both an additive and a relative error for concentrations and only an additive error for ventilation. All values in the PKePD analysis are median (SEE ¼ standard error of the estimate); P-values < 0.01 were considered significant. The analyses were performed simultaneously on remifentanil/esketamine and remifentanil/placebo data in multiple steps (with estimation of interoccasion variability for the remifentanil model parameters). (i) First the esketamine PK data were analysed using a three-compartment model. Initially, the structural parameters of Sigtermans and colleagues 19 were implemented, after which we searched for systematic deviations from that model. (ii) For remifentanil, it was assumed that the target-controlled infusion values correctly reflect the plasma concentrations. (iii) For both esketamine (E) and remifentanil (R), a possible hysteresis between plasma concentration and effect was modelled by assuming effect compartments with blood-effect-site equilibration half-times, t½ E and t½ R , respectively. (iv) Next, the population PD model parameters were determined with fixed empirical Bayesian individual drug PK model parameters. Inspired minute ventilation ( _ V E ) was modelled as 20 :
where _ V BLN is baseline ventilation obtained without any inspired CO 2 , S the ventilatory carbon dioxide sensitivity, P T CO 2 the CO 2 concentration at the site of chemoreception (and instantaneously related to _ V E ) and P TB CO 2 the baseline value of P T CO 2 . In our isohypercapnic experiments, P T CO 2 was assumed to be constant over time, hence (P T CO 2 eP TB CO 2 ) is a constant. We next assume that remifentanil depresses ventilation by an effect on _ V BLN , S, or both:
where C REM is the remifentanil effect-site concentration and C 50 1 the concentration remifentanil that _ V BLN by 50%, C 50 2 the concentration remifentanil that reduces S by 50%, G1 and G2 shape factors and l a constant. Since the effect of remifentanil on S and _ V BLN may effectively occur at separate sites in the brainstem, we postulated two distinct equilibration halftimes, t½ R1 and t½ R2 .
We assume that esketamine may increase C 50 1 or C 50 2 as follows:
where C 50 1(0) and C 50 2(0) are the respective remifentanil C 50 1 and C 50 2 values when the esketamine effect-site concentration is zero, C KET the esketamine effect-site concentration, C K D 1 and C K D 2 the esketamine effect-site concentrations causing a doubling of C 50 1 and C 50 2, respectively, and Q a shape factor.
The effect of placebo on remifentanil-induced respiratory depression was modelled as follows:
where C P is the assumed esketamine concentration during placebo treatment.
A mixture analysis was performed on C K D 2 with four possible response subgroups. An individual can be a ketamine responder or non-responder, and a placebo responder or nonresponder, giving four possibilities. The mixture analysis was done in NONMEM, by specifying: (i) the probability of being a ketamine responder and the probability of being a placebo responder; and (ii) the C K D 2 values of the four subgroups: an estimable parameter for ketamine, an estimable parameter for placebo, and a fixed potency of zero (corresponding to a C K D 2 of infinity) for the (ketamine and placebo) non-responders. The probability parameters are estimated by NONMEM by minimising the objective function as usual. In addition, NONMEM estimates to which of the four subgroups the individuals are the most likely to belong, on the basis of which the ketamine/ placebo responder/non-responder status of the subjects were assessed and counted. The choice of C K D 2 for mixture analysis was based on the objective functions of the various models that were tested. These models included: (i) a model in which remifentanil had an effect at a single component Y vs an effect at Y1 and Y2; (ii) a model with an esketamine effect on C (iv) a model in which Q was not fixed vs Q fixed to 1; (v) a model in which esketamine was compared with placebo without any mixture analysis vs the mixture analysis as described above; and (vi) a model in which placebo and esketamine data were grouped with a mixture analysis with two possible groups (responders and non-responders) vs a model with mixture analysis with four groups as described above.
We calculated normalised prediction discrepancies (NPD; by NONMEM) as a visual predictive check of the final esketamine model. 21, 22 In brief, 300 Monte Carlo simulations (of the final model output based on the fixed and distributions of the random effects) were performed and the number of times an observation is greater than the model prediction is counted. The NPD are the counts divided by 300, transformed via the inverse normal distribution. Under the null hypothesis that the model is correct, the NPD should have a normal distribution. It was checked by visual inspection that the NPD vs time showed no trends, heteroscedasticity, or both.
Results
Sixteen subjects of either sex were enrolled in the study. Two subjects ended their participation during screening because of facemask discomfort, two others because of esketamineinduced psychomimetic side effects. Their data were discarded. The 12 participating subjects (six men, six women) had a mean age of 24 (range 20e31) yr, weight of 68 (52e102) kg and body mass index of 22 (19e30) kg m À2 . All 12 subjects completed the study without major side effects.
Side effects
Side effects included nausea (occurred on seven occasions), headache (two occasions) and anxiety (one occasion). Mean drug high VRS scores (SD) were: remifentanil/esketamine 7.2 (1.9), remifentanil/placebo 1.9 (2.3; P<0.001 vs remifentanil/ esketamine) and esketamine (visit 3) 6.9 (2.5; P¼0.75 vs remifentanil/esketamine). Sedation VRS scores were remifentanil/ esketamine 7.0 (2.5), remifentanil/placebo 3.7 (2.4; P<0.001 vs remifentanil/esketamine) and esketamine (visit 3) 6.3 (2.6; P¼0.18 vs remifentanil/esketamine).
Effect of esketamine vs placebo on remifentanilinduced respiratory depression
The average esketamine concentrations are given in Figure 1A ; mean (SD) peak plasma esketamine concentration was 381 (65) ng ml À1 . The end-tidal PCO 2 values were similar between treatments: mean end-tidal PCO 2 esketamine 6.6 (0.4) kPa vs Figure 1B and C demonstrate that esketamine but not placebo antagonised remifentanil-induced respiratory depression. Remifentanil had similar effects in the two arms of the study with a reduction from 19.9 (0.4) to 12. In both treatment arms, remifentanil affected both ventilatory frequency and tidal volume (Supplementary Fig. S2 ). In the remifentanil/esketamine and remifentanil/placebo arms, remifentanil reduced ventilatory frequency from 17.1 (3.7) to 14.7 (3.1) bpm (P<0.01) and 17.5 (2.9) to 14.9 (2.5) bpm (P<0.01), respectively, and tidal volume from 1220 (283) to 853 (955) ml (P<0.01) and 1150 (222) to 812 (113) ml (P<0.01), respectively. Esketamine had a selective effect on ventilatory frequency with an increase from 14.7 (3.1) to 18.6 (3.9) (P<0.01). Tidal volume showed a small albeit insignificant increase 853 (156) to 955 (396) ml by esketamine. Placebo had no effect on either ventilatory frequency or tidal volume.
PKePD analysis
The PK parameter estimates are given in Supplementary  Table S1 . The parameter estimates of the final threecompartment model were similar to that of Sigtermans and colleagues, 19 with the exception of the clearances that were 83
(2)% of the earlier estimates. Goodness of fit plots are given in Figure 2AeC , showing measured vs individually predicted esketamine concentrations ( Fig. 2A) , conditional weighted residuals with heε interaction (CWRESI) vs time (Fig. 2B ) and the NPD (Fig. 2C) . All indicate that the model adequately described the data. The best PD model (Table 1 and Supplementary Table S2 ) is a mixture model with remifentanil effect on Y1 and Y2, an esketamine effect on C K D 2 (i.e. Y2) and Q fixed to 1. The PD parameter estimates of the best model are given in Table 1 . Examples of data fits are given in Figure 3 for an esketamine responder (Fig. 3A , median fit with R 2 ¼0.719), an esketamine non-responder (Fig. 3b) , a placebo responder (Fig. 3C ) and a placebo non-responder (Fig. 3D , best fit with R 2 ¼0.952). Goodness of fit plots are given in Fig. 3DeF . Inspection of the individual fits and the goodness of fit plots indicate that the model adequately described the data.
Remifentanil effect
The model has two ventilation components [Y1 and Y2, equations (2) and (3)] at which remifentanil acted. The effect of remifentanil was 39% at Y2 and 61% at Y1 [compare parameter l of equation (4) Fig. 3D , a Table 1 Pharmacodynamic parameter estimates. _ V BLN is baseline ventilation, C 50 1 is the remifentanil concentration causing a 50% decline of V BLN , C 50 2 is the remifentanil concentration causing a 50% decline the ventilatory CO 2 sensitivity, t½ R1 and t½ R2 are the blood-effect-site equilibration half-times linked to components Y1 and Y2, respectively [equations (1) and (2)], G1 and G2 are shape factors of components Y1 and Y2, respectively [equations (1) and (2) (3) and (4) placebo experiment, where an initial rapid decrease in ventilation is followed by a slow further decline. The absence of an Y1 component in some subjects is explained by the fact that the slow component was only present when target remifentanil concentrations were relatively high and occurred with a steep concentrationeresponse relationship. This reflected by the relatively high values of parameter estimates C 50 1 and G1.
Esketamine and placebo effects
Esketamine had an exclusive effect on component Y2 and doubled C 50 2 at a concentration of 127 (34) ng ml À1 ðC K D 2Þ; an effect on C 50 1 was not identifiable. Esketamine blood-effectsite equilibration half-time (t½ E ) was not significantly different from 0, indicative that the esketamine effect was driven by plasma PK. In some subjects, a response to placebo treatment was observed (see Fig. 3C for an example). To quantify the placebo effect, it was assumed that esketamine was present and had an effect of C 50 2. This led to a placebo potency parameter C K D 2ðplaceboÞ with value 363 (37.5) ng ml À1 , a factor of 3 smaller than the esketamine C K D 2: Probability of being a responder to esketamine or placebo was 83 (12)% and 23 (15)%, respectively, which corresponds to 10 responders to esketamine and three to placebo.
Doseeresponse relationship
To get an indication of the steady-state doseeresponse relationships, the two inputs to the PD model are plotted against ventilation in Figure 4 . Figure 4A gives the target remifentanil concentrationeventilation relationship at several esketamine concentrations (ranging from 0 to 400 ng ml À1 ); Figure 4B gives the esketamine concentrationeventilation relationship at a number of target remifentanil concentrations (ranging from 0 to 2 ng ml À1 ). In both Figure 4A and B, the maximum observed concentrations are depicted by the grey broken lines. All values beyond these lines are extrapolations. Figure 4C combines the data from Figure 4A and B and gives the response surface of esketamine concentration (y-axis), target remifentanil concentration (x-axis) against ventilation (z-axis).
Effect of esketamine on poikilocapnic ventilation
Esketamine plasma concentrations of the observational study were similar to those observed in the randomised trial (Fig. 1A) , with peak plasma concentrations of 378 (24) ng ml
À1
. Esketamine induced a small decrease in end-tidal PCO 2 of 0.4 kPa from 5.2 (0.3) kPa (baseline) to 4.8 (0.4) kPa (last minute of esketamine infusion; paired t-test: P<0.01) but had no effect on ventilation [ _ V BLN changed from 8.9 (0.6) litre min À1 (baseline) to 9.4 (1.6) litre min À1 (last minute of esketamine infusion), P¼0.12]. Changes in ventilation and end-tidal PCO 2 were restricted to the final minute of the highest esketamine infusion (Fig. 1D ).
Discussion
The main findings from our study are that esketamine dosedependently reverses remifentanil-induced respiratory depression, while it has a little or no effect when ventilation is not depressed by the opioid.
PD model
Remifentanil effect
We constructed a PD model in which both remifentanil and esketamine could affect breathing via actions at component Y1, component Y2 [equations (2e4)], or both. We observed that remifentanil reduced ventilation via an effect at both parts, at Y1 with relatively low potency and slow dynamics, and at Y2 with relatively high potency and faster dynamics ( Table 1) . The initial rapid decrease in ventilation after the start of remifentanil infusion is a result of its effect on Y2, while the slow decrease in ventilation that was observed in some subjects was a result of an effect at Y1. In mammals, ventilatory control has CO 2 -sensitive and CO 2 -insensitive components as described in equation (1), where _ V BLN is the CO 2 -insensitive and S the CO 2 -sensitive component. 18, 23, 24 In our analysis, we link a drug effect at Y1 to an action at CO 2 -insensitive ventilation, while an effect at Y2 is linked to the CO 2 -sensitive operator of ventilation. These associations seem hypothetical but are plausible when we take the results of visit 3 into account where esketamine had little effect on resting ventilation (i.e. Y1 or _ V BLN ); see also the following section (Esketamine effect).
We did not directly estimate the value of S in our analysis.
However, parameter l is an indirect estimate of S. Since lÂY2¼SÂ(P T CO 2 eP TB CO 2 ) z 8 litre min
À1
, the value of S is estimated to be approximately 8 litre min À1 kPa À1 (assuming that P T CO 2 eP TB CO 2 z1 kPa), 24 which is within the range of ventilatory CO 2 sensitivities observed in healthy young volunteers. 24 The reason for a difference in remifentanil potency and dynamics at components Y1 and Y2 remains unknown but could be related to the opioid effect on central neuronal dynamics, causing a slow reduction of CO 2 -insensitive ventilation. 25 Previously we tested the effect of remifentanil on ventilation in open loop conditions. 26 The remifentanil effect in that study was modelled with just one component with values for C 50 (1.6 ng ml À1 ) and t½ R (0.53 min) in the same range as in the current study for Y2. We relate the inability to detect a slow component (Y1) to the short infusion times (0.5e6 min) and open loop (i.e. poikilocapnic) conditions in that study. With respect to the latter condition, any slow reduction in ventilation might have been counteracted by the slow increase in arterial CO 2 . Apparently, the open-loop PD model was unable to detect such a slow effect, if at all it occurred in these short infusion experiments.
Esketamine effect
Esketamine (at a cumulative dose of 40 mg) exclusively impacted on Y2. We argue that (low-dose) esketamine interacts with the ventilatory control system under conditions that the central respiratory network is affected by an opioid (i.e. under conditions of hypoventilation). We come to this conclusion as the same esketamine dose had only a limited effect under ); the combination of ketamine and morphine had an additive negative effect on breathing. 31 Using CO 2 -rebreathing, Hamza and colleagues 35 showed a 40% reduction of the slope of the _ V E À CO2 response by an anaesthetic dose of racemic ketamine (2 mg kg À1 followed by 0.04 mg kg À1 min À1 ) in a paediatric population (age 6e10 yr). We previously observed in mice that esketamine produced a dose-dependent reduction of the _ V E À CO2 response slope in a dose range of 10e200 mg kg
À1
, with frequent inspiratory pauses in the higher dose range. 32 Differences in species, dose, ketamine formulation or experimental set-up can only explain part of the differences in study outcomes. For example, our cumulative esketamine dose of 0.57 mg kg À1 esketamine falls well within the dose range studied by Bourke and colleagues, 31 even when taking into account a possible potency difference between racemic ketamine and the S(þ)-isomer. 36 Possibly, ketamine's metabolites are involved in the respiratory effects of the parent drug (see item (iii) in paragraph "Mechanism of esketamine-induced respiratory depression"). If so, then differences in PK among species and between isomers may explain some of the observed differences. It is important to realise that we and others observed a ketamine-induced stimulatory effects on breathing at subanaesthetic ketamine doses. 13, 15 In rats,
Eikermann and colleagues 14 showed that respiratory stimulation persists even at anaesthetic doses, while Hamza and colleagues 35 found the reverse in children. Further human studies are needed to fully understand the complex behaviour of the low-and high-dose ketamine isomers on breathing. An interesting observation is that, in contrast to remifentanil, which reduced both tidal volume and ventilatory frequency, esketamine selectively increased ventilatory frequency ( Supplementary Fig. S2 ). It has recently been proposed that tidal volume is regulated by metabolic stimuli, while respiratory frequency is driven by fast non-metabolic factors. 37, 38 Our findings then suggest that remifentanil has a metabolic effect, while the esketamine effect was related to non-metabolic stimuli (e.g. stress, behavioural stimuli, or both). This seems to disagree with the findings of this study that esketamine increased ventilatory CO 2 sensitivity, which is a component of metabolic control. 38 Additionally, the proposed mechanisms of esketamine-induced respiratory stimulation all seem metabolic in nature (see below). Possibly, behavioural effects of isohypercapnia may have affected the study outcome. However, all subjects who completed the study were highly comfortable during all three visits. Further studies are needed to address the mechanistic pathway of esketamine within the ventilatory control system. Extrapolation of our results to higher remifentanil concentrations suggests that even in case of the complete cessation of breathing (i.e. opioid-induced apnoea), low-dose ketamine may restore breathing activity (Fig. 4) . Further studies are needed to verify the validity of our model at deep levels of respiratory depression (e.g. at remifentanil plasma concentrations >1.25 ng ml À1 ). If corroborated, ketamine behaves similarly to CX717, an ampakine that restores respiratory activity following fentanyl-induced apnea. 10 However, ketamine does not appear to act like drugs that exert their effect at the carotid bodies or drugs with reduced efficacy at deeper levels of opioid-induced respiratory depression (i.e. ceiling behavior).
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Mechanism of esketamine-induced respiratory stimulation
Although our study was not specifically designed to unearth the mechanism of the stimulatory effect of esketamine on breathing, it is relevant to discuss possible mechanisms. (i) Esketamine produces a strong increase in sympathetic outflow and reduces the reuptake of neuronal norepinephrine. 19 Monoaminergic neurotransmitters play an important role in ventilatory control. 40 Increased synaptic concentrations of noradrenaline stimulate breathing activity and increase ventilatory CO 2 reactivity. 41, 42 (ii) Esketamine may stimulate breathing though N-methyl-D-aspartate receptor blockade. Some indirect evidence comes from an animal model of the Rett syndrome. 43 Patients with Rett syndrome have mental retardation and experience severe breathing irregularities because to mutations in the MECP2 gene. In a mouse model of Rett syndrome, ketamine reduced the number of apnoeic events by actively stimulation of breathing activity. (iii) Finally, it may well be that the esketamine metabolite hydroxynorketamine contributed to the respiratory effects of the parent drug. Hydroxynorketamine is an agonist at the AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor. 44 AMPA receptors are expressed in the brainstem respiratory network, for example within the pre-B€ otzinger complex, an area of the brain involved in respiratory rhythmogenesis, and play an important role in the maintenance of respiratory drive. 45, 46 Of interest is the observation that so called ampakines, drugs that act selectively at the AMPA receptors, increase the respiratory drive in both animal and human studies, but, as stated earlier, only under conditions of hypoventilation. 29, 30 For example, the ampakine CX717 counters alfentanil-induced respiratory depression to a 50% depression of _ V E À CO2 sensitivity. 29 An effect of esketamine via hydroxynorketamine at AMPA receptors may explain the absence of response in some subjects who are poor metabolisers. This remains speculative at present, as we did not measure hydroxynorketamine plasma concentrations in our subjects. Future studies will need to resolve whether hydroxynorketamine plays an important role in the respiratory effects of ketamine. If so, this would mirror the observation in rodents that hydroxynorketamine rather than ketamine plays a major role in the generation of its antidepressant effects. 44 In summary, we observed that remifentanil depressed ventilation in healthy volunteers by reducing ventilatory CO 2 sensitivity, an effect that was partially countered by esketamine. These findings could indicate that the use of low-dose esketamine in postoperative patients may not only reduce opioid consumption but will also stabilise breathing and consequently reduce the probability of fatal events. The esketamine dose needed for such an effect is between 12 and 24 mg h À1 (for a 70 kg patient). However, the observed advantageous effects of esketamine should be balanced against its side effect profile, most importantly the psychedelic symptoms that may be perceived by some patients as extremely frightful. We believe that additional studies are still needed and we plan to construct esketamine utility functions to determine the optimal esketamine dose that produces respiratory stimulation with minimal side effects. 47, 48 
